Key Laboratory of Analysis and Detection for Food Safety, Ministry of Education & Fujian Province, Department of Chemistry, Fuzhou University, Fuzhou 350108, PR China.
Biosens Bioelectron. 2014 Mar 15;53:465-71. doi: 10.1016/j.bios.2013.10.027. Epub 2013 Oct 24.
Prostate-specific antigen (PSA), one of the indications of possible prostate malignancy, is used as a biomarker for the diagnosis and prognosis of prostate cancer. Herein, we develop a new homogeneous potentiometric immunoassay for sensitive detection of low-concentration PSA without the need of sample separation and washing step. Two nanostructures including positively charged polyethyleneimine-poly(styrene-co-acrylic acid) (PEI-PSAA) nanospheres and negatively charged gold nanoparticles conjugated with anti-PSA antibody (Ab-AuNP) were first synthesized by using mulsifier-free emulsion copolymerization and wet chemistry method, respectively. Thereafter, the as-prepared PEI-PSAA was used as a pseudo hapten for the construction of immunosensing probe based on an electrostatic interaction between PEI-PSAA and Ab-AuNP. Upon target introduction, the added PSA competed with PEI-PASS for Ab-AuNP based on a specific antigen-antibody interaction, and displaced Ab-AuNP from PEI-PASS. The dissociated PEI-PASS was captured through the negatively charged Nafion- modified electrode, thereby resulting in the change of membrane potential. The fabrication process was characterized by using high-resolution transmission electron microscope (HRTEM), scanning electron microscope with energy-dispersive X-ray spectroscopy (SEM-EDX), surface plasmon resonance (SPR) and dynamic laser scattering (DLS) technique. Under optimal conditions, the output signal was indirectly proportional to the concentration of target PSA in the sample and exhibited a dynamic range from 0.1 to 50 ng/mL with a detection limit (LOD) of 0.04 ng/mL. Intra- and inter-assay coefficients of variation (CVs) were 6.8 and 7.5%, respectively. In addition, the methodology was evaluated for analysis of 12 clinical serum samples and showed good accordance between the results obtained by the developed immunosensing protocol and a commercialized enzyme-linked immunosorbent assay (ELISA) method.
前列腺特异性抗原(PSA)是前列腺恶性肿瘤的可能指标之一,用作前列腺癌的诊断和预后的生物标志物。在此,我们开发了一种新的均相电势免疫测定法,用于灵敏检测低浓度 PSA,无需样品分离和洗涤步骤。首先通过无乳化剂乳液共聚和湿化学方法分别合成了带正电荷的聚乙烯亚胺-聚(苯乙烯-co-丙烯酸)(PEI-PSAA)纳米球和带负电荷的金纳米粒子与抗 PSA 抗体(Ab-AuNP)结合的两种纳米结构。此后,将制备的 PEI-PSAA 用作基于 PEI-PSAA 和 Ab-AuNP 之间的静电相互作用的免疫传感探针构建的伪半抗原。引入靶标后,加入的 PSA 与 PEI-PASS 基于特定的抗原-抗体相互作用竞争 Ab-AuNP,并将 Ab-AuNP 从 PEI-PASS 中置换出来。解离的 PEI-PASS 通过带负电荷的 Nafion 修饰电极捕获,从而导致膜电位发生变化。通过高分辨率透射电子显微镜(HRTEM)、带有能量色散 X 射线光谱(SEM-EDX)的扫描电子显微镜、表面等离子体共振(SPR)和动态激光散射(DLS)技术对制备过程进行了表征。在最佳条件下,输出信号与样品中目标 PSA 的浓度呈间接比例,显示出 0.1 至 50ng/mL 的动态范围,检测限(LOD)为 0.04ng/mL。内和间测定的变异系数(CV)分别为 6.8%和 7.5%。此外,该方法用于分析 12 个临床血清样本的评估,并显示出开发的免疫传感方案与商业化酶联免疫吸附测定(ELISA)方法之间的良好一致性。